Oral Tirzepatide Class Action: Judge Denies Arbitration, Keeps SkinnyRx RICO Suit in Federal Court
On Nov. 18, 2026, Chief Judge Matthew Brann refused to compel arbitration in Freeland v. Foothills Professional Pharmacy, the oral tirzepatide class action over SkinnyRx pills, holding a checkout "Continue" click is not assent, and let the RICO, fraud and UTPCPL claims proceed.
Courts Desk··14 min read

A federal judge in Pennsylvania ruled on Nov. 18, 2026 that the companies behind SkinnyRx's oral tirzepatide pills cannot force buyers into individual arbitration, so the oral tirzepatide class action in Freeland v. Foothills Professional Pharmacy, Ltd. will proceed in court as a proposed nationwide class. Chief Judge Matthew W. Brann of the Middle District of Pennsylvania denied both motions to compel arbitration and largely denied the motions to dismiss, keeping alive RICO, fraud, unjust enrichment and Pennsylvania consumer protection claims against a compounding pharmacy, a telehealth technology company, a clinician network and a physician.
The ruling is one of the first merits-stage decisions in the wave of consumer suits over compounded "oral" versions of tirzepatide, the active ingredient in Eli Lilly's injectable Mounjaro and Zepbound. It is also a fresh data point for anyone who drafts or attacks online checkout flows: according to plaintiffs' counsel, the court held that tapping a button labeled "Continue" did not signal agreement to arbitrate. Below is what the court decided, how the arbitration holding fits Third Circuit law, what was trimmed, and what happens next.
What did the court decide in the SkinnyRx oral tirzepatide class action?
Chief Judge Brann resolved four sets of motions in one order. The defendants named on the docket are Foothills Professional Pharmacy, Ltd.; Avocado Health Technology, Inc.; Sajad Zalzala, M.D.; TeleRx Providers, P.C.; and Does 1-5. Foothills moved separately; Avocado, Dr. Zalzala and TeleRx moved together.
| Motion | Movant | Result |
|---|---|---|
| Motion to compel arbitration (ECF 76) | Foothills Professional Pharmacy | Denied |
| Motion to compel arbitration (ECF 39) | Avocado Health Technology, Dr. Zalzala, TeleRx Providers | Denied |
| Motion to dismiss | Foothills | Granted in part, denied in part |
| Motion to dismiss | Avocado, Dr. Zalzala, TeleRx | Granted in part, denied in part |
The bottom line, as summarized by Bloomberg Law, Law360 and plaintiffs' firm Chimicles Schwartz Kriner & Donaldson-Smith LLP, is that the core of the case survived. The claims that go forward are:
- civil RICO, on the theory that the four defendants operated a coordinated enterprise to market and sell the pills nationwide;
- violation of Pennsylvania's Unfair Trade Practices and Consumer Protection Law (UTPCPL), with one theory limited;
- common-law fraud; and
- unjust enrichment.
Two pieces were cut back. The court dismissed without prejudice the claims brought for a proposed subclass of consumers in 14 other states, and it narrowed one UTPCPL theory. Freeland has 21 days from the order to file an amended complaint curing the deficiencies in Count VI, the count pleading violations of multiple state consumer protection statutes.
Why did the judge refuse to compel arbitration?
The defendants' arbitration clause sat in online terms that buyers encountered during the purchase flow. The question for any Motion to Compel Arbitration built on a website is formation: did the consumer actually agree? Under Section 2 of the Federal Arbitration Act (FAA), an arbitration agreement is enforceable only if a contract was formed under ordinary state-law principles, and the party seeking arbitration bears the burden of showing it.
According to the Chimicles summary of the opinion, Chief Judge Brann held that clicking "Continue" at checkout did not bind consumers to arbitrate, because a reasonable consumer would not understand the word "continue" to mean "agree." That reasoning tracks the two-part test that federal courts apply to online contracts: (1) whether the website gave reasonably conspicuous notice of the terms, and (2) whether the user took an action that unambiguously manifested assent to them. A button that names a navigational step, rather than an acceptance, tends to fail the second prong unless the surrounding text expressly says that clicking it means agreement.
The written opinion is posted on govinfo, but because full-text access to it was not available for this report, the analysis below relies on consistent accounts of the holding from the plaintiffs' firm and two legal news services. No figure or quotation in this article comes from an unverified source.
How does the ruling fit Third Circuit law on online arbitration terms?
The Middle District of Pennsylvania sits within the U.S. Court of Appeals for the Third Circuit, and three lines of authority frame the decision.
James v. Global Tel*Link Corp., 852 F.3d 262 (3d Cir. 2017). The Third Circuit held that telephone users of an inmate-calling service had not agreed to arbitration terms posted online, because the service never told them that using it meant accepting those terms. The court treated the arrangement like a browsewrap and found no mutual assent. James stands for the proposition that the mere existence of terms somewhere on a website is not enough.
Kirkham v. TaxAct (3d Cir. 2025). In the other direction, the Third Circuit found that an interface with checkboxes and conspicuous hyperlinks at account creation and e-filing gave reasonably conspicuous notice and manifested assent. The panel also reinforced the Third Circuit's procedural rule from Guidotti v. Legal Helpers Debt Resolution, L.L.C., 716 F.3d 764 (3d Cir. 2013): when formation is genuinely disputed, the district court should allow limited discovery on arbitrability before ruling, and the question may be decided under a summary judgment standard.
Persuasive "Continue" button authority. The most-cited case on a bare "Continue" button is the Ninth Circuit's Berman v. Freedom Financial Network, LLC (2022), which affirmed denial of a motion to compel where the button's label did not tell users that clicking it meant agreement to terms. Earlier this month, in Nader v. LendingTree, a Ninth Circuit panel again refused arbitration because website design prevented mutual assent, keeping data breach claims in MDL 3126. Freeland applies the same logic to a telehealth checkout inside the Third Circuit.
The practical message is consistent across circuits: a "Continue," "Next" or "Place Order" button is enforceable as assent only if adjacent, legible text says that clicking it constitutes agreement to the linked terms. Without that sentence, a court can find no contract at all, and arguments about Unconscionability, a Delegation Clause or a Class Action Waiver never come into play, because there is nothing to enforce.
Who are the defendants and what does the complaint allege?
Cynthia Freeland filed the complaint on Feb. 3, 2026 in the Williamsport division of the Middle District of Pennsylvania on behalf of herself and a proposed nationwide class of purchasers. Her counsel lists SkinnyRx among the consumer-facing brands whose buyers may be class members; SkinnyRx itself is not a named defendant.
The theory of the case is structural. The complaint alleges that four actors worked together:
- Foothills Professional Pharmacy, Ltd., a compounding pharmacy that allegedly made and shipped the tablets;
- Avocado Health Technology, Inc., a telehealth technology company that allegedly ran the platform;
- TeleRx Providers, P.C., a clinician network that allegedly supplied prescribers; and
- Sajad Zalzala, M.D., a physician alleged to be part of the prescribing arrangement.
The complaint alleges that oral tirzepatide, sold as tablets and orally dissolving tablets, was marketed as an effective GLP-1 weight-loss medication when no FDA-approved oral tirzepatide exists and, plaintiffs contend, the compound is functionally inert when swallowed. Tirzepatide is a peptide; the FDA-approved products are weekly injections, and the clinical trials behind them did not test any oral formulation. Whether the pills deliver a clinically meaningful dose is an allegation that has not yet been tested with evidence.
Is the oral tirzepatide class action preempted by federal drug law?
No, at least at the pleading stage. According to Bloomberg Law, Chief Judge Brann rejected the defendants' argument that the Federal Food, Drug, and Cosmetic Act (FDCA) preempts the state-law claims.
Compounders often invoke two related defenses. The first is implied preemption under Buckman Co. v. Plaintiffs' Legal Committee (2001) and 21 U.S.C. § 337(a), which bars private suits that exist solely to enforce the FDCA. The second is that compounding under Sections 503A and 503B is lawful, so a claim premised on "unapproved drug" status is really an attempt to police FDA's turf. The usual answer, and the one that carried the day here, is that fraud, consumer protection and RICO claims rest on independent state-law and federal-law duties not to misrepresent a product. A claim that a seller promised weight loss from a pill that cannot deliver it does not depend on the FDCA's existence, so it does not run into Buckman. Defendants that hoped Preemption (Products) would end the case early will now have to fight on the facts.
What was dismissed, and what happens next?
The procedural road from here has three forks.
Amendment. Freeland has 21 days to replead Count VI. The dismissal of the 14-state subclass was without prejudice, which typically signals a pleading defect, such as a failure to tie each state statute to a named plaintiff with standing or to plead the elements that vary state by state, rather than a merits rejection.
Interlocutory appeal of the arbitration ruling. Under 9 U.S.C. § 16(a)(1), an order refusing to compel arbitration is immediately appealable as of right to the Third Circuit. Under Coinbase, Inc. v. Bielski, 599 U.S. 736 (2023), a timely appeal automatically stays district court proceedings while the appeal is pending. That means the defendants hold a lever: a notice of appeal within 30 days would pause discovery and class certification briefing, possibly for a year or more.
Discovery and class certification. If no appeal is taken, or once it is resolved, the case moves to discovery on the alleged enterprise, the formulations, and the marketing claims, and then to a Rule 23 motion. Class Certification will turn on predominance: whether the alleged misrepresentation was uniform across the checkout and marketing pages, and whether reliance can be presumed or proved on a class-wide basis under RICO and Pennsylvania law.
| Date | Event |
|---|---|
| Nov. 2025 | Separate oral tirzepatide class action filed in the District of Delaware against OpenLoop Health and Triad Rx |
| Feb. 3, 2026 | Freeland complaint filed in M.D. Pa., No. 4:26-cv-00263 |
| Feb. 20, 2026 | FDA warning letter to Lean Rx, Inc. d/b/a SkinnyRx |
| March 3, 2026 | FDA announces 30 warning letters to telehealth companies over compounded GLP-1 marketing |
| June 2026 | FDA issues a further round of 25 warning letters on compounded GLP-1 claims |
| Nov. 18, 2026 | Chief Judge Brann denies arbitration and largely denies dismissal |
| ~Dec. 9, 2026 | 21-day deadline to amend Count VI |
| ~Dec. 18, 2026 | 30-day window for a notice of appeal under FAA § 16 and FRAP 4(a)(1)(A) |
The last two dates are computed from the order date and are approximate; the operative deadlines run from entry on the docket.
What did the FDA say about SkinnyRx?
On Feb. 20, 2026, the FDA sent a warning letter to Lean Rx, Inc., doing business as SkinnyRx (MARCS-CMS 717989). The agency objected that compounded semaglutide and tirzepatide pictured on the SkinnyRx website carried a "SkinnyRx" label, suggesting SkinnyRx was the compounder of the drugs when it was not, which the FDA treated as misbranding. The letter was one of 30 the agency announced on March 3, 2026 against telehealth companies for false or misleading marketing of compounded GLP-1 products, including claims implying equivalence to FDA-approved drugs. A further round of 25 warning letters followed in June 2026.
A warning letter is not a finding of liability, and it is not binding in a civil case. It matters in Freeland in two practical ways. It gives plaintiffs a public, agency-authored account of how the products were presented to consumers, which is useful at the plausibility and class certification stages. And it undercuts any defense framing that the marketing was ordinary or regulator-approved.
How does Freeland compare with other oral GLP-1 lawsuits?
Freeland is not alone. The closest parallel is Day v. OpenLoop Health Inc. in the U.S. District Court for the District of Delaware, filed in November 2025. Plaintiff Darby Day alleges he paid $279.99 for a one-month supply of oral tirzepatide through MEDVi, a telehealth brand that is not a defendant, and sues OpenLoop Health Inc., Triad Rx Buyer LLC and Triad Rx Inc. under RICO and consumer protection laws. The defendants moved to dismiss, describing the suit as an effort to turn dissatisfaction with a prescription weight-loss treatment into a federal RICO case and arguing that compounding is lawful. Eli Lilly, which is not a party, told Fierce Healthcare there are no human studies of any oral tirzepatide product.
| Feature | Freeland v. Foothills (M.D. Pa.) | Day v. OpenLoop (D. Del.) |
|---|---|---|
| Filed | Feb. 3, 2026 | Nov. 2025 |
| Consumer brand | SkinnyRx (not a defendant) | MEDVi (not a defendant) |
| Defendants | Compounding pharmacy, telehealth tech company, clinician network, physician | White-label telehealth services company and two Triad Rx pharmacy entities |
| Core claims | RICO, UTPCPL, multistate consumer statutes, fraud, unjust enrichment | RICO, multistate consumer statutes, fraud |
| Arbitration | Motions to compel denied Nov. 18, 2026 | Not reported as contested |
| Status | Proceeding; amendment window open | Motion to dismiss pending as last reported |
These consumer-fraud cases are distinct from the GLP-1 personal injury litigation. Injury claims against the makers of FDA-approved drugs (gastroparesis and related gastrointestinal injuries, and vision loss including NAION) are centralized in the Eastern District of Pennsylvania in Multidistrict Litigation (MDL) 3094 and MDL 3163. The oral tirzepatide suits do not allege physical injury; they allege that buyers paid for a product that does not work as advertised.
Does the ruling open the door to mass arbitration or class claims for buyers?
It points toward class litigation, not Mass Arbitration. Had the motions been granted, each purchaser would have been confined to individual arbitration, and the only way to pursue the claims at scale would have been a coordinated wave of individual demands, with the business typically bearing most of the Filing Fee and Case Management Fee for each one under consumer rules. Because the court found no agreement to arbitrate, at least for the checkout flow before it, there is no clause to file under. The claims stay in court, and class members who do nothing remain in the putative class.
Two caveats apply. First, the ruling concerns the specific interface Freeland used; if the defendants changed their checkout later, later purchasers may face a different analysis, which can complicate class definitions. Second, if the Third Circuit reverses on appeal, the case would split into individual arbitrations, and mass filing would become the realistic path for buyers' counsel.
What it means for telehealth companies, compounders and plaintiffs' counsel
For drafters and telehealth operators. The lesson is not new, but Freeland shows the cost of ignoring it. The checkout button that completes payment should carry an explicit assent statement, such as "By clicking Place Order, you agree to the Terms of Service, including the Arbitration Agreement," positioned directly above or beside the button, in legible type, with the hyperlink visibly marked. A clickwrap checkbox remains the most defensible design. Companies that also want protection against mass filings should pair clear assent with a modern Mass Arbitration Protocol, but none of those provisions helps if formation fails.
For compounding pharmacies and their platform partners. The RICO enterprise theory reached a physician, a clinician network and a technology vendor, not just the pharmacy. Platform contracts that allocate marketing responsibility, indemnity and insurance will matter. The preemption defense failed at the pleading stage, so the defense will turn to the evidence: formulation data, absorption studies, and what each defendant actually said to buyers.
For plaintiffs' and claimants' counsel. A denied Motion to Compel Arbitration is often the most valuable ruling in a consumer case, because it keeps the class device available. The next pressure points are likely a Section 16 appeal and the Coinbase stay. Counsel in parallel oral GLP-1 cases can use Freeland to test the defendants' own checkout flows early, before arguing the merits.
For litigation funders and portfolio investors. Compounded GLP-1 consumer claims have a small Claim Value per buyer, often a few hundred dollars per month of product, which makes them Negative-Value Claims that are viable only on a class basis. The arbitration ruling is therefore the gating event for case economics, and a Third Circuit appeal would extend the timeline.
FAQ
Is there an oral tirzepatide class action lawsuit?
Yes. Freeland v. Foothills Professional Pharmacy, Ltd., No. 4:26-cv-00263, is a proposed nationwide class action in the Middle District of Pennsylvania over oral tirzepatide tablets sold through SkinnyRx, and Day v. OpenLoop Health is a similar proposed class action in the District of Delaware over pills sold through MEDVi.
Can SkinnyRx buyers be forced into arbitration?
Not under the Nov. 18, 2026 ruling. Chief Judge Brann denied both motions to compel arbitration, finding, according to plaintiffs' counsel, that clicking "Continue" at checkout did not create an agreement to arbitrate. The defendants may appeal that order to the Third Circuit.
Is SkinnyRx a defendant in the lawsuit?
No. The named defendants are Foothills Professional Pharmacy, Avocado Health Technology, TeleRx Providers and Dr. Sajad Zalzala. SkinnyRx, operated by Lean Rx, Inc., is identified as a consumer-facing brand through which the pills were sold, and it received a separate FDA warning letter dated Feb. 20, 2026.
Is oral tirzepatide FDA-approved?
No. The FDA-approved tirzepatide products, Mounjaro and Zepbound, are injections. There is no FDA-approved oral tirzepatide, which is a central allegation in both pending class actions.
What claims survived in the Freeland case?
The RICO, Pennsylvania UTPCPL, fraud and unjust enrichment claims survived. The court dismissed without prejudice the claims of a proposed 14-state subclass, limited one UTPCPL theory, and gave the plaintiff 21 days to amend the multistate consumer protection count.
How do I join the oral tirzepatide class action?
No class has been certified, so there is nothing to join or opt out of yet. Purchasers are putative class members while the case is pending; if a class is certified or a settlement is reached, the court will order Class Notice describing who is included and any deadlines.
Published for legal professionals. Analysis and summaries only — not legal advice, and no attorney-client relationship is created by use of this site.
Read next

LendingTree Arbitration Ruling: Ninth Circuit Keeps Snowflake Breach Claims in the Montana MDL
On Nov. 4, 2026, a Ninth Circuit panel in Nader v. LendingTree affirmed that LendingTree and QuoteWizard cannot compel arbitration of Snowflake data breach claims, finding their websites never produced mutual assent, so the claims stay in MDL 3126.
Courts Desk · 13 min

Rugs.com Arbitration Ruling: Ninth Circuit Says a 'Join Now' Email Sign-Up Did Not Bind Shoppers
In Perkins v. Rugs.com, the Ninth Circuit on Oct. 28, 2026 affirmed the denial of Rugs.com's motion to compel arbitration, holding that entering an email address and clicking 'Join Now' beside a Terms of Use link was not assent under Washington law.
Courts Desk · 13 min

FDA Orders GLP-1 NAION Warning: What the Label Change Means for the 278-Case Vision-Loss Lawsuit MDL
On November 9, 2026 the FDA required every GLP-1 drug label to warn of a potential increased risk of NAION. The GLP-1 NAION warning lawsuit docket, MDL No. 3163, now has a federal label change at the center of its failure-to-warn and preemption fight.
Torts Desk · 14 min